



TECHNICAL MANUAL

4-1BB Bioassay, Propagation Model

Instructions for Use of Product
J2332

4-1BB Bioassay, Propagation Model

All technical literature is available at: www.promega.com/protocols/
 Visit the website to verify that you are using the most current version of this Technical Manual.
 Email Promega Technical Services if you have questions on use of this system: techserv@promega.com

1.	Description	2
2.	Product Components and Storage Conditions	8
3.	Before You Begin	9
3.A.	Materials to Be Supplied by the User	10
3.B.	Preparing 4-1BB Effector Cells	11
4.	Assay Protocol for FcγRIIb-Dependent Antibodies	12
4.A.	Preparing Assay Buffer, Bio-Glo™ Reagent and Antibody Samples	13
4.B.	Plate Layout Design	15
4.C.	Preparing and Plating FcγRIIb CHO-K1 Cells	15
4.D.	Preparing Antibody Serial Dilutions	16
4.E.	Preparing 4-1BB Effector Cells	17
4.F.	Adding Antibody Samples and 4-1BB Effector Cells to Assay Plates	18
4.G.	Adding Bio-Glo™ Reagent	18
4.H.	Data Analysis	18
5.	Assay Protocol for Ligand or FcγRIIb-Independent Antibodies	19
5.A.	Preparing Assay Buffer, Bio-Glo™ Reagent and Antibody Samples	19
5.B.	Plate Layout Design	21
5.C.	Preparing Ligand or Antibody Serial Dilutions	21
5.D.	Preparing 4-1BB Effector Cells	23
5.E.	Adding Ligand or Antibody Samples and 4-1BB Effector Cells to Assay Plates	23
5.F.	Adding Bio-Glo™ Reagent	24
5.G.	Data Analysis	24
6.	Troubleshooting	25
7.	References	26
8.	Appendix	27
8.A.	Representative Assay Results with FcγRIIb-Dependent Antibody	27
8.B.	Representative Assay Results with Crosslinked 4-1BB Ligand	28
8.C.	Composition of Buffers and Solutions	29
9.	Summary of Changes	29

1. Description

The human immune system is regulated by a complex network of inhibitory and stimulatory receptors that facilitate the elimination of pathogens, while maintaining tolerance to self-antigens. Stimulatory immune checkpoint receptors appear to have a significant role in cancer progression and autoimmune disease. Several co-stimulatory immune checkpoint receptors such as Glucocorticoid-induced TNF receptor family-related protein (GITR), 4-1BB, OX40, CD40 and Inducible T-cell costimulator (ICOS) have been identified. Activating these receptors with ligands or agonist antibodies has emerged to be the next generation of immunotherapeutic strategy to enhance anti-tumor immune responses and promote immune-mediated tumor rejection (1–3).

4-1BB (CD137/TNFRSF9), a member of the tumor necrosis factor receptor superfamily, is an inducible co-stimulatory receptor expressed on T cells, natural killer (NK) cells and innate immune cell populations (4). When present on the cell surface, 4-1BB interacts with 4-1BB ligand (4-1BBL), and induces subsequent cell proliferation and production of interferon gamma (IFN γ) and IL-2, particularly in T and NK cells (5,6).

Current methods used to measure the activity of biologic drugs targeting 4-1BB rely on primary human T cells and measurement of functional endpoints such as cell proliferation, cell surface marker expression, and interferon gamma (IFN γ) and interleukin-2 (IL-2) production. These assays are laborious and highly variable due to their reliance on donor primary cells, complex assay protocols and unqualified assay reagents. As a result, these assays are difficult to establish in a drug-development setting.

The antibodies used to stimulate T cell activation via interaction with co-stimulatory receptors on the effector cells, can be crosslinked via binding to Fc γ RIIb receptors on CHO-K1 cells. This crosslinking increases avidity and stabilizes the interaction of the antibody to the receptor, in certain cases (7,8).

The 4-1BB Bioassay, Propagation Model^(a-e) (Cat.# J2332), is a bioluminescent cell-based assay that overcomes the limitations of existing assays and can be used to measure the potency and stability of ligands or agonist antibodies that can bind and activate 4-1BB (6,9). The assay consists of a genetically engineered Jurkat T cell line that expresses human 4-1BB and a luciferase reporter driven by a response element that can respond to 4-1BB ligand/agonist antibody stimulation. The 4-1BB Effector Cells are provided in Cell Propagation Model (CPM) format, which includes cryopreserved cells that can be thawed, propagated and banked for long-term use.

The 4-1BB Bioassay should be conducted with FcγRIIb CHO-K1 Cells (Cat.# J2232) to test whether agonist antibodies activate 4-1BB in an FcγRIIb-dependent manner. FcγRIIb CHO-K1 cells may be required to crosslink agonist antibodies but are not required for testing ligands. It is recommended that when screening for agonist antibodies of co-stimulatory immune checkpoints, you perform the assay both with and without FcγRIIb CHO-K1 cells to ascertain the need for these cells in enhancing the effect of the agonist antibodies raised against the co-stimulatory immune checkpoint targets.

Induction of the 4-1BB Effector Cells with a 4-1BB ligand or agonist antibody results in response element-mediated luminescence (Figure 1). The bioluminescent signal is quantified using the Bio-Glo™ Luciferase Assay System and a standard luminometer such as the GloMax® Discover System.

The 4-1BB Bioassay, Propagation Model, reflects the mechanism of action (MOA) of biologics designed to activate 4-1BB. Specifically, 4-1BB-mediated luminescence is detected following the addition of 4-1BB agonist antibodies and 4-1BB ligand, respectively (Figure 2). The bioassay is prequalified according to ICH guidelines and shows the precision, accuracy and linearity required for routine use in potency and stability studies (Table 1 and Figure 3). The assay can be performed in a one-day or two-day time frame depending on antibody properties. The bioassay workflow is simple and robust, and compatible with both 96- and 384-well plate formats used for antibody screening in early drug discovery (Figure 4). In addition, the bioassay can be used with up to 100% human serum (in antibody samples) with minimal impact on fold induction (Figure 5), indicating potential for further development into a neutralizing antibody bioassay.

1. Description (continued)




Figure 1. Representation of the 4-1BB Bioassay. Panel A. Assay with FcγRIIb-dependent agonist antibody. The bioassay consists of two engineered cell lines, 4-1BB Effector Cells and FcγRIIb CHO-K1 Cells. In the presence of FcγRIIb CHO-K1 Cells, the anti-4-1BB antibody can be crosslinked, thereby inducing 4-1BB pathway-activated luminescence. **Panel B.** Assay with FcγRIIb-independent agonist antibody or ligand. The bioassay consists of one engineered cell line, 4-1BB Effector Cells. In the absence of agonist antibody or 4-1BB ligand, the 4-1BB receptor is not activated and luminescence signal is low. The addition of agonist antibody or 4-1BB ligand induces the 4-1BB pathway-activated luminescence, which can be detected in a dose-dependent manner.




Figure 2. The 4-1BB Bioassay reflects the mechanism of action (MOA) and shows specificity of biologics designed to activate 4-1BB. **Panel A.** 4-1BB Effector Cells were induced, respectively, with a serial titration of ligands: GITRL, 4-1BBL and OX40L as indicated. **Panel B.** 4-1BB Effector Cells were induced, respectively, with a serial titration of anti-GITR antibody, Control Ab, Anti-4-1BB (Cat. # K1161) and anti-OX40 antibody, as indicated, in the presence of FcγRIIb CHO-K1 Cells (Cat. # JA2251). Bio-Glo™ Reagent was added, and luminescence was quantified using the GloMax® Discover System. Data were generated using thaw-and-use cells and fitted to a 4-parameter logistic curve using GraphPad Prism® software.

Table 1. The 4-1BB Bioassay Shows Precision, Accuracy and Linearity.

Parameter	Results	
	% Expected Relative Potency	% Recovery
Accuracy	50	106.0
	70	96.2
	140	97.3
	200	103.2
Repeatability (% CV)	100% (Reference)	3.5
Intermediate Precision (% CV)		6.6
Linearity (r ²)		0.996
Linearity (y = mx + b)		y = 1.025x - 1.835
<p>A 50–200% theoretical potency series of Control Ab, Anti-4-1BB, was analyzed in triplicate in three independent experiments performed on three days by two analysts. Bio-Glo™ Reagent was added, and luminescence was quantified using the GloMax® Discover System. Data were analyzed and relative potencies were calculated after parallelism determination using JMP® software. Data were generated using thaw-and-use cells.</p>		

1. Description (continued)




Figure 3. The 4-1BB Bioassay is stability-indicating. Samples of Control Ab, Anti-4-1BB (Cat.# K1161), were maintained at 4°C (control) or heat-treated at 68°C for indicated times, and then analyzed using the 4-1BB Bioassay with FcγRIIb CHO-K1 Cells (Cat.# JA2251). Bio-Glo™ Reagent was added and luminescence was quantified using the GloMax® Discover System. Data were generated using thaw-and-use cells and fitted to a four-parameter logistic curve using GraphPad Prism® software.




Figure 4. The 4-1BB Bioassay is amenable to 384-well plate format and compatible with laboratory automation.

Panel A. The 4-1BB Bioassay was performed in 96-well plates as described in this technical manual using Control Ab, Anti-4-1BB. **Panel B.** The 4-1BB Bioassay was performed in 384-well format using a Mantis[®] liquid handler to dispense the cells and Echo[®] Acoustic liquid handler for antibody handling. On the day before assay, FcγRIIb CHO-K1 Cells (Cat. # JA2251) were plated at 8×10^3 cells/10 μl /well. On the day of the assay, Control Ab, Anti-4-1BB (Cat. # K1161), was serially diluted and added to the plate at 0.2 μl /well. Finally, 4-1BB effector cells were added at 1.0×10^4 cells/10 μl /well. After a 6-hour incubation, 20 μl of Bio-Glo[™] Reagent was added, and luminescence was quantified using the GloMax[®] Discover System. Data were fitted to a four-parameter logistic curve using GraphPad Prism[®] software. The EC_{50} values were 0.13 $\mu\text{g/ml}$ and 0.095 $\mu\text{g/ml}$, and the fold inductions were 103 and 58 for 96- and 384-well format, respectively. Data were generated using thaw-and-use cells.

1. Description (continued)




Figure 5. The 4-1BB Bioassay is tolerant to human serum. **Panel A.** 4-1BB ligand (4-1BBL, R&D Systems Cat.#2295-4L-025/CF) was analyzed in the presence of increasing concentrations of pooled normal human serum (0–100% in the ligand sample), resulting in final assay concentration of human serum (0–33.3%). **Panel B.** Control Ab, Anti-4-1BB was analyzed in the presence of Fc γ RIIb CHO-K1 Cells (Cat.# JA2251) and increasing concentrations of pooled normal human serum (0–100% in the antibody sample), resulting in final assay concentration of human serum (0–33.3%). Bio-Glo™ Reagent was added, and luminescence was quantified using the GloMax® Discover System. Data were fitted to a four-parameter logistic curve using GraphPad Prism® software. Data were generated using thaw-and-use cells. The 4-1BB Bioassay is tolerant to serum with this human serum pool. A different human serum pool showed similar effects on the assay (data not shown).

2. Product Components and Storage Conditions

PRODUCT	SIZE	CAT.#
4-1BB Bioassay, Propagation Model	1 each	J2332

Not for Medical Diagnostic Use.

Includes:

- 2 vials 4-1BB Effector Cells (CPM), 2.0×10^7 cells/ml (1.0ml per vial)

Note: Thaw and propagate one vial to create frozen cell banks before use in an assay. The second vial should be reserved for future use.

Storage Conditions: Upon arrival, immediately transfer the cell vials to below -140°C (freezer or liquid nitrogen vapor phase) for long-term storage. Do not store cell vials submerged in liquid nitrogen. **Do not** store cell vials at -80°C because this will decrease cell viability and cell performance.

3. Before You Begin

Please read through the entire protocol to become familiar with the components and the assay procedure before beginning.

Note the catalog number and lot number from the cell vial box label. This information can be used to download documents for the specified product from the website such as Certificate of Analysis.

The 4-1BB Bioassay, Propagation Model, is intended to be used with user-provided antibodies or ligands designed to activate 4-1BB. Control Ab, Anti-4-1BB (Cat.# K1161) and FcγRIIb CHO-K1 Cells (Cat.# J2232) are available separately for use in assay optimization and routine quality control. We strongly recommend including 4-1BB Ligand or Control Ab, Anti-4-1BB, and FcγRIIb CHO-K1 Cells as a positive control in the first few assays to gain familiarity with the assay. Data generated using these reagents are shown in Figures 2–5 and Sections 8.A and 8.B, Representative Assay Results.

Cell thawing, propagation and banking should be performed exactly as described in Section 3. Cell seeding and propagation densities have been optimized to ensure stable cell growth, which is reflected in a steady cell doubling rate, to achieve optimal, consistent performance. An accurate, reliable, and reproducible cell counting method is required for routine cell culturing and optimal bioassay performance. The recommended cell plating densities, induction time and assay buffer components described in Sections 4 and 5 were established using 4-1BB Ligand and Control Ab, Anti-4-1BB, respectively. You may need to adjust the parameters provided here and optimize assay conditions for your own antibody or biologic.

The 4-1BB Bioassay produces a bioluminescent signal and should work with all major luminometers or luminescence plate readers for the detection of luminescence. Bioassay development and performance data included in this Technical Manual were generated using the GloMax® Discover System. An integration time of 0.5 second/well was used for all readings.

3.A. Materials to Be Supplied by the User

(Composition of buffers and solutions is provided in Section 8.C.)

Reagents

- user-defined anti-4-1BB antibodies or other biologics samples
- RPMI 1640 Medium with L-glutamine and HEPES (e.g., Corning® Cat.# 10-041-CV or GIBCO® Cat.# 22400105)
- Ham's F-12 Medium with L-glutamine (e.g., GIBCO® Cat.# 11765062)
- fetal bovine serum (e.g., HyClone Cat.# SH30070.03 or GIBCO® Cat.# 16000044)
- hygromycin B (e.g., GIBCO® Cat.# 10687010)
- G418 sulfate solution (e.g., GIBCO® Cat.# 10131035)
- sodium pyruvate (e.g., GIBCO® Cat.# 11360070)
- MEM nonessential amino acids, 100X (e.g., GIBCO® Cat.# 11140050)
- DMSO (e.g., Sigma Cat.# D2650)
- DPBS (e.g., GIBCO® Cat.# 14190)
- Accutase® solution (e.g., Sigma Cat.# A6964)
- Trypan blue solution (e.g., Sigma Cat.# T8154)
- Bio-Glo™ Luciferase Assay System (Cat.# G7940, G7941)
- **optional:** FcγRIIb CHO-K1 Cells (If using this assay for the first time and/or testing an Ab that might be dependent on crosslinking FcγRIIb, use this cell line; Cat.# JA2251)
- **optional:** control 4-1BB ligand/TNFSF9 with His tag (R&D Systems, Cat.# 2295-4L-025/CF)
- **optional:** anti-His tag Ab for crosslinking control 4-1BB ligand (Biolegend, Cat.# 652502)

Supplies and Equipment

- solid-white, flat-bottom 96-well assay plates (e.g., Corning® Cat.# 3917) for plating and reading luminescence
- sterile clear V-bottom 96-well plate with lid (e.g., Costar® Cat.# 3896 or Linbro Cat.# 76-223-05) for preparing antibody dilutions
- pipettes (single-channel and 12-channel; for best results use both manual and electronic pipettes as needed)
- sterile 15ml and 50ml conical tubes
- sterile reagent reservoirs (e.g., Costar®/Corning® Cat.# 4870)
- 37°C, 5% CO₂ incubator
- 37°C water bath
- plate reader with glow luminescence measuring capability or luminometer (e.g., GloMax® Discover System or equivalent system)

3.B. Preparing 4-1BB Effector Cells



Follow institutional guidelines for handling, including use of personal protective equipment (PPE), and waste disposal for biohazardous material.

Cell Thawing and Initial Cell Culture

1. Prepare 50ml of initial cell culture medium by adding 5ml of FBS, 0.5ml of 100X MEM nonessential amino acids (NEAA) and 0.5ml of 100mM sodium pyruvate to 44ml of RPMI 1640 medium prewarmed to 37°C. This initial cell culture medium will be used for culturing the cells immediately after thawing.
2. Transfer 9ml of prewarmed initial cell culture medium to a 50ml conical tube.
3. Remove one vial of 4-1BB Effector Cells from storage at -140°C and thaw in a 37°C water bath with gentle agitation (no inversion) until just thawed (typically 2–3 minutes).
4. Transfer all of the cells (approximately 1ml) to the 50ml conical tube containing 9ml of prewarmed initial cell culture medium.
5. Centrifuge at $90 \times g$ for 10 minutes.
6. Carefully aspirate the medium, and resuspend the cell pellet in 25ml of prewarmed initial cell culture medium.
7. Transfer the cell suspension to a T75 tissue culture flask, and place the flask horizontally in a 37°C, 5% CO₂ incubator.
8. Incubate for approximately 48 hours before passaging the cells.

Cell Maintenance and Propagation

Note: For cell maintenance and propagation starting from the second cell passage, use the cell growth medium containing antibiotics and monitor cell viability and doubling rate during propagation. The cell growth rate will stabilize by 7–10 days post-thaw, at which time cell viability is typically >90%, and the average cell doubling rate is ~36 hours. Passage number should be recorded for each passage. In our experience, cells maintain their functionality for up to 25 passages if passaging is performed on a Monday-Wednesday-Friday schedule.

9. On the day of cell passage, measure cell viability and density by Trypan blue staining.
10. Seed the cells at a density of 6×10^5 cells/ml if passaging every 2 days (e.g., Monday-Wednesday or Wednesday-Friday) or 4×10^5 cells/ml if passaging every 3 days (e.g., Friday-Monday). Always maintain the flasks in a horizontal position in the incubator.
11. Maintain the cell culture by adding fresh cell growth medium to the cell suspension in the original flask or by transferring the cells to a new flask while maintaining a consistent ratio of culture volume to flask surface area (e.g., 25ml volume per T75 flask or 50ml volume per T150 flask).
12. Place the flasks horizontally in a 37°C, 5% CO₂ incubator.

3.B. Preparing 4-1BB Effector Cells (continued)

Cell Freezing and Banking

13. On the day of cell freezing, make fresh cell freezing medium and keep on ice.
14. Gently mix the cells with a pipette to create a homogenous cell suspension.
15. Remove a sample for cell counting by Trypan blue staining. Calculate the volume of cell freezing medium needed based on desired cell freezing densities of 1×10^7 – 3×10^7 cells/ml.
16. Transfer the cell suspension to 50ml sterile conical tubes or larger sized centrifuge tubes, and centrifuge at $130 \times g$, 4°C , for 10–15 minutes.
17. Carefully aspirate the supernatant; avoid disturbing the cell pellet.
18. Gently resuspend the cell pellet in ice-cold cell freezing medium to a final cell density of 1×10^7 – 3×10^7 cells/ml. Combine the cell suspensions into a single tube and dispense into cryovials.
19. Freeze the cells using a controlled-rate freezer (preferred), or a Mr. Frosty® or a Styrofoam® rack in a -80°C freezer overnight. Transfer the vials to at or below -140°C for long-term storage.

4. Assay Protocol for FcγRIIb-Dependent Antibodies

This assay protocol requires two engineered cell lines: 4-1BB Effector Cells and FcγRIIb CHO-K1 Cells. The FcγRIIb CHO-K1 Cells are provided in Thaw-and-Use format and CPM format (see *FcγRIIb CHO-K1 Propagation Model Technical Manual*, #TM569, for details), and either format can be used in this assay.

The procedure below illustrates the use of the 4-1BB Bioassay to test two FcγRIIb-dependent antibody samples against a reference sample in a single assay run using the FcγRIIb CHO-K1 Cells CPM format. Each test and reference antibody is run in triplicate, in a ten-point dilution series, in a single 96-well assay plate using the inner 60 wells. Other experimental and plate layouts are possible but may require further optimization.

Note: When preparing test and reference antibodies, choose an appropriate starting concentration and dilution scheme to achieve a complete dose-response curve with proper upper and lower asymptotes and sufficient points on the slope. For reference, we use $10\mu\text{g/ml}$ as a starting concentration (1X) and threefold serial dilution when testing Control Ab, Anti-4-1BB.

4.A. Preparing Assay Buffer, Bio-Glo™ Reagent and Antibody Samples

1. **FcγRIIb CHO-K1 Cell Recovery Medium:** On the day before the assay, prepare 40ml of cell recovery medium (90% Ham's F-12/10% FBS) in a 50ml conical tube. Thaw the FBS overnight at 4°C or in a 37°C water bath on the day of use. Add 4ml of FBS to 36ml of Ham's F-12 medium. Mix well and warm to 37°C before use.
2. **Assay Buffer:** On the day of the assay, prepare an appropriate amount of assay buffer (99% RPMI 1640/1% FBS). Thaw the FBS overnight at 4°C or in a 37°C water bath on the day of use. Mix well and warm to 37°C before use. For reference, 30ml of assay buffer is typically sufficient for 120 wells in a 96-well assay format using the inner 60 wells.

Note: The recommended assay buffer contains 1% FBS. This concentration of FBS works well for the Control Ab, Anti-4-1BB, that we tested.

3. **Bio-Glo™ Reagent:** For reference, 10ml of Bio-Glo™ Reagent is sufficient to assay 120 wells in a 96-well assay format. Thaw the Bio-Glo™ Luciferase Assay Buffer at 4°C overnight or in a room temperature water bath on the day of assay. Equilibrate the Bio-Glo™ Luciferase Assay Buffer to ambient temperature, protected from light.

Transfer all of the Bio-Glo™ Luciferase Assay Buffer into the amber bottle containing the Bio-Glo™ Luciferase Assay Substrate and mix by inversion until the Substrate is thoroughly dissolved. Equilibrate and store the reconstituted Bio-Glo™ Reagent at ambient temperature (22–25°C) protected from light before adding to assay plates.

If you are using a large (100ml) size of Bio-Glo™ Luciferase Assay System, dispense the reconstituted Bio-Glo™ Reagent into 10ml aliquots and store at –20°C for up to six weeks. Avoid repeated freeze-thaw cycles. On the day of the assay, thaw an appropriate amount of reconstituted Bio-Glo™ Reagent in a room temperature water bath for at least 1–2 hours before use. The Bio-Glo™ Reagent can be stored at room temperature after reconstitution with only ~18% loss in luminescence after 24 hours.

4. **Test and Reference Samples:** Using assay buffer as the diluent, prepare starting dilutions (dilu1, 3X final concentration) of two test antibodies (180µl each) and one reference antibody (400µl) in 1.5ml tubes. Store the tubes containing antibody starting dilutions appropriately before making antibody serial dilutions.

Notes:

- a. If you are using Control Ab, Anti-4-1BB, as a reference antibody in your assay, prepare a 400µl starting dilution with 30µg/ml of anti-4-1BB antibody (dilu1, 3X final concentration) by adding 12µl of anti-4-1BB stock (1,000µg/ml) to 388µl of assay buffer. Store the antibody starting dilution on ice until ready to use in the assay.
- b. To streamline assay setup, prepare antibody serial dilutions prior to harvesting and plating 4-1BB Effector cells.




Figure 6. Schematic protocol for 4-1BB Bioassay with Fc γ RIIb-dependent antibody.

4.B. Plate Layout Design

For the protocol described here, use the plate layout illustrated in Figure 7 as a guide. The protocol describes serial replicate dilutions (n = 3) of test and reference antibody to generate two ten-point dose-response curves for each plate.

Recommended Plate Layout Design													
	1	2	3	4	5	6	7	8	9	10	11	12	
A	B	B	B	B	B	B	B	B	B	B	B	B	Assay Buffer (B)
B	B	no Ab	dilu9	dilu8	dilu7	dilu6	dilu5	dilu4	dilu3	dilu2	dilu1	B	Reference Ab
C	B	no Ab	dilu9	dilu8	dilu7	dilu6	dilu5	dilu4	dilu3	dilu2	dilu1	B	Test Ab
D	B	no Ab	dilu9	dilu8	dilu7	dilu6	dilu5	dilu4	dilu3	dilu2	dilu1	B	Reference Ab
E	B	no Ab	dilu9	dilu8	dilu7	dilu6	dilu5	dilu4	dilu3	dilu2	dilu1	B	Test Ab
F	B	no Ab	dilu9	dilu8	dilu7	dilu6	dilu5	dilu4	dilu3	dilu2	dilu1	B	Reference Ab
G	B	no Ab	dilu9	dilu8	dilu7	dilu6	dilu5	dilu4	dilu3	dilu2	dilu1	B	Test Ab
H	B	B	B	B	B	B	B	B	B	B	B	B	Assay Buffer (B)

Figure 7. Example plate layout showing nonclustered sample locations of test antibody and reference antibody dilution series and wells containing assay buffer (denoted by “B”) alone.

4.C. Preparing and Plating FcγRIIb CHO-K1 Cells

While maintaining the FcγRIIb CHO-K1 Cells (Cat.# J2232), follow the cell seeding density recommendations in this section. Changes in cell culture volume or seeding density will affect cell growth rate and assay performance. Do not allow the cells to grow to 100% confluence. Only use the cells in the assay after the cell doubling rate has stabilized during propagation.

! **Note:** Perform the following steps in a sterile cell culture hood.

1. We recommend passaging the FcγRIIb CHO-K1 Cells two days before plating for the assay, as described in the *FcγRIIb CHO-K1 Cells Propagation Model Technical Manual*, #TM569, to ensure optimal and consistent assay performance.
2. On the day before performing the assay, prepare new FcγRIIb CHO-K1 cell recovery medium (90% Ham’s F-12/10% FBS) for the FcγRIIb CHO-K1 Cells.
3. Aspirate the cell culture medium from the FcγRIIb CHO-K1 Cells and wash with DPBS.

4.C. Preparing and Plating FcγRIIb CHO-K1 Cells (continued)

4. Add 2ml of Accutase® solution to each T75 flask, and place the flask in a 37°C, 5% CO₂ incubator for 5–7 minutes or until the cells round up and detach from the bottom of the flask.
5. Add 8ml of FcγRIIb CHO-K1 cell recovery medium to the flask. Transfer the cell suspension to a 50ml (or larger) conical centrifuge tube.
6. Gently mix and count the FcγRIIb CHO-K1 Cells by Trypan blue staining.
7. Centrifuge at 230 × g for 5 minutes.
8. Gently resuspend the cell pellet in cell recovery medium to achieve a concentration of 4 × 10⁵ viable cells/ml.
9. Transfer the suspension to a sterile reagent reservoir. Using a multichannel pipette, immediately dispense 100µl of the cell suspension to each of the inner 60 wells of a 96-well white flat-bottom assay plate. The final cell number in each well should be 4 × 10⁴ cells/well.
10. Add 100µl of cell recovery medium to each of the outside wells of the assay plates.
11. Place lids on the assay plates and incubate in a 37°C, 5% CO₂ incubator overnight (18–22 hours).

4.D. Preparing Antibody Serial Dilutions

The instructions described here are for preparation of a single stock of threefold serial dilutions of a single antibody for analysis in triplicate (120µl of each antibody dilution provides a sufficient volume for analysis in triplicate). Alternatively, you can prepare three independent stocks of serial dilutions to generate triplicate samples. To prepare threefold serial dilutions, you will need 400µl of reference antibody at 3X the highest antibody concentration in your dose-response curve. You will need 180µl of each test antibody at 3X the highest antibody concentration for test antibody dose-response curves. For other dilution schemes, adjust the volumes accordingly.

Note: If you are using Control Ab, Anti-4-1BB, as a control in the assay, follow the instructions below to prepare threefold serial dilutions. A threefold serial dilution for test antibodies was listed as an example below as well.

1. On the day of assay, prepare an appropriate amount of assay buffer as described in Section 4.A.
2. To a sterile, clear V-bottom 96-well plate, add 180µl of reference antibody starting dilution (dilu1, 3X final concentration) to wells A11 and B11 (see Figure 8).
3. Add 180µl of test antibodies 1 and 2 starting dilution (dilu1, 3X final concentration) to wells E11 and G11, respectively (see Figure 8).
4. Add 120µl of assay buffer to other wells in these four rows, from column 10 to column 2.
5. Transfer 60µl of the antibody starting dilutions from column 11 into column 10. Mix well by pipetting. Avoid creating bubbles.
6. Repeat equivalent threefold serial dilutions across the columns from right to left through column 3. Do not dilute into column 2.
7. Cover the assay plate with a lid and keep at ambient temperature (22–25°C) while preparing the 4-1BB Effector Cells.

Note: Wells A2, B2, E2 and G2 contain 120µl of assay buffer without antibody as a negative control.

4.D. Preparing Antibody Serial Dilutions (continued)

Recommended Plate Layout for Antibody Dilutions Prepared from a Single Antibody Stock													
	1	2	3	4	5	6	7	8	9	10	11	12	
A		no Ab	dilu9	dilu8	dilu7	dilu6	dilu5	dilu4	dilu3	dilu2	dilu1		Reference Ab
B		no Ab	dilu9	dilu8	dilu7	dilu6	dilu5	dilu4	dilu3	dilu2	dilu1		Reference Ab
C													
D													
E		no Ab	dilu9	dilu8	dilu7	dilu6	dilu5	dilu4	dilu3	dilu2	dilu1		Test Ab 1
F													
G		no Ab	dilu9	dilu8	dilu7	dilu6	dilu5	dilu4	dilu3	dilu2	dilu1		Test Ab 2
H													

Figure 8. Example plate layout showing antibody serial dilutions.

4.E. Preparing 4-1BB Effector Cells

While maintaining the 4-1BB Effector Cells, it is important to follow the recommended cell seeding density. Changes in cell culture volume or seeding density will affect cell growth rate and assay performance. Only use the cells in the assay after the cell doubling rate has stabilized during propagation.

Note: Passaging cells less than 40 hours before assay is not recommended for this specific assay.

1. Passage the cells 2 days or 3 days before performing the assay as described in Section 3.B. To ensure optimal and consistent assay performance, maintain the cell density, upon harvest, in the range of $1.5\text{--}2.0 \times 10^6$ cells/ml and cell viability at greater than 90%.
2. Count the 4-1BB Effector Cells by Trypan blue staining, and calculate the cell density and viability.
3. Transfer an appropriate amount of 4-1BB Effector Cells from the culture vessel to a 50ml conical tube or larger sized centrifuge tube.
4. Collect the cells at $130 \times g$ for 10 minutes at ambient temperature, and resuspend the pellet in assay buffer to generate the targeted cell density of 1.0×10^6 cells/ml.
5. You will need at least 8ml of 4-1BB Effector Cells to fill 120 assay wells, or the inner 60 wells of two assay plates.

4.F. Adding Antibody Samples and 4-1BB Effector Cells to Assay Plates

1. Take the 96-well assay plates containing FcγRIIb CHO-K1 Cells out of the incubator. Using a manual multichannel pipette, remove 95µl of medium from each of the wells. Alternatively, invert the assay plate above a sink to remove the medium. Then, place the inverted plate on paper towels for 5–10 seconds to drain any remaining medium.
2. Using an electronic multichannel pipette, add 25µl of the appropriate antibody titration to the assay plates according to the plate layout in Figure 7.
3. Add 75µl of assay buffer to the outside wells of the 96-well assay plates.
4. Transfer the 4-1BB Effector Cells prepared in Section 4.E to a sterile reagent reservoir. Using a multichannel pipette, dispense 50µl (0.5×10^5 cells) of 4-1BB Effector Cells into the wells containing antibody.
5. Cover the assay plates with lids and incubate in a 37°C, 5% CO₂ incubator for 6 hours.

4.G. Adding Bio-Glo™ Reagent

Note: Bio-Glo™ Reagent should be at ambient temperature (22–25°C) when added to assay plates.

1. Take the assay plates out of the incubator and equilibrate to ambient temperature for 10–15 minutes.
2. Using a manual multichannel pipette, add 75µl of Bio-Glo™ Reagent to the inner 60 wells of the assay plates, taking care not to create bubbles.
3. Add 75µl of Bio-Glo™ Reagent to wells B1, C1 and D1 of each assay plate to measure the background signal.
4. Incubate at ambient temperature for 5–15 minutes.
Note: Varying the incubation time will affect the raw relative light unit (RLU) values but should not significantly change the EC₅₀ value and fold induction.
5. Measure luminescence using a luminometer or luminescence plate reader.

4.H. Data Analysis

1. Determine the plate background by calculating the average RLU from wells B1, C1 and D1.
2. Calculate fold induction =
$$\frac{\text{RLU (induced-background)}}{\text{RLU (no antibody control-background)}}$$
3. Graph data as RLU versus Log₁₀ [antibody] and fold induction versus Log₁₀ [antibody]. Fit curves and determine the EC₅₀ value of antibody response using appropriate curve fitting software (such as GraphPad Prism® software).

5. Assay Protocol for Ligand or FcγRIIb-Independent Antibodies

This assay protocol illustrates the use of the 4-1BB Bioassay to test two antibody samples against a reference sample in a single assay run. Each test and reference antibody is run in triplicate, in a ten-point dilution series, in a single 96-well assay plate using the inner 60 wells. Other experimental and plate layouts are possible but may require further optimization.

Note: When preparing test antibodies or ligand, choose an appropriate starting concentration and dilution scheme to achieve a full dose-response curve with proper upper and lower asymptotes and sufficient points on the slope. For reference, we use 1 µg/ml as a starting concentration (1X) and threefold dilution when testing 4-1BB Ligand.

5.A. Preparing Assay Buffer, Bio-Glo™ Reagent and Antibody Samples

1. **Assay Buffer:** On the day of the assay, prepare an appropriate amount of assay buffer (99% RPMI 1640/1% FBS). Thaw the FBS overnight at 4°C or in a 37°C water bath on the day of use. Mix well and warm to 37°C before use. For reference, 30ml of assay buffer is typically sufficient for 120 wells in a 96-well assay format using the inner 60 wells.

Note: The recommended assay buffer contains 1% FBS. This concentration of FBS works well with the crosslinked Control Ligand, 4-1BBL, that we tested.

2. **Bio-Glo™ Reagent:** For reference, 10ml of Bio-Glo™ Reagent is sufficient to assay 120 wells in a 96-well assay format. Thaw the Bio-Glo™ Luciferase Assay Buffer at 4°C overnight or in a room temperature water bath on the day of assay. Equilibrate the Bio-Glo™ Luciferase Assay Buffer to ambient temperature, protected from light.

Transfer all of the Bio-Glo™ Luciferase Assay Buffer into the amber bottle containing the Bio-Glo™ Luciferase Assay Substrate and mix by inversion until the substrate is thoroughly dissolved. Equilibrate and store the reconstituted Bio-Glo™ Reagent at ambient temperature (22–25°C) protected from light before adding to assay plates.

If you are using a large (100ml) size of Bio-Glo™ Luciferase Assay System, dispense the reconstituted Bio-Glo™ Reagent into 10ml aliquots and store at –20°C for up to six weeks. Avoid repeated freeze-thaw cycles. On the day of the assay, thaw an appropriate amount of reconstituted Bio-Glo™ Reagent in a room temperature water bath for at least 1–2 hours before use. The Bio-Glo™ Reagent can be stored at room temperature after reconstitution with only ~18% loss in luminescence after 24 hours.

3. **Test and Reference Samples:** Using assay buffer as the diluent, prepare starting dilutions (dilu1, 3X final concentration) of two test antibodies (180µl each) and one reference crosslinked ligand (400µl) in 1.5ml tubes. Store the tubes containing ligand or antibody starting dilutions appropriately before making antibody serial dilutions.

Notes:

- a. If you are using 4-1BBL as a reference ligand, prepare a 400µl starting dilution with 3µg/ml 4-1BBL (His-tagged) and 15µg/ml crosslinking antibody, anti-His (dilu1, 3X final concentration) by adding 12µl of 4-1BBL, stock (100µg/ml) and 12µl of crosslinking antibody, anti-His stock (500µg/ml) to 376µl of assay buffer. The final (1X) starting concentration is 1µg/ml of 4-1BBL and 5µg/ml of anti-His Ab. Store the antibody starting dilution on ice until ready to use in the assay.
- b. To streamline assay setup, prepare antibody or ligand serial dilutions prior to harvesting and plating cells.

5.A. Preparing Assay Buffer, Bio-Glo™ Reagent and Antibody Samples (continued)




Figure 9. Schematic protocol for 4-1BB Bioassay with 4-1BB Ligand or FcγRIIb-independent antibody.

5.B. Plate Layout Design

For the protocol described here, use the plate layout illustrated in Figure 10 as a guide. The protocol describes serial replicate dilutions ($n = 3$) of test antibody and reference ligand to generate two ten-point dose-response curves for each plate.

Recommended Plate Layout Design													
	1	2	3	4	5	6	7	8	9	10	11	12	
A	B	B	B	B	B	B	B	B	B	B	B	B	Assay Buffer (B)
B	B	no Ab	dilu9	dilu8	dilu7	dilu6	dilu5	dilu4	dilu3	dilu2	dilu1	B	Reference Ligand
C	B	no Ab	dilu9	dilu8	dilu7	dilu6	dilu5	dilu4	dilu3	dilu2	dilu1	B	Test Ab
D	B	no Ab	dilu9	dilu8	dilu7	dilu6	dilu5	dilu4	dilu3	dilu2	dilu1	B	Reference Ligand
E	B	no Ab	dilu9	dilu8	dilu7	dilu6	dilu5	dilu4	dilu3	dilu2	dilu1	B	Test Ab
F	B	no Ab	dilu9	dilu8	dilu7	dilu6	dilu5	dilu4	dilu3	dilu2	dilu1	B	Reference Ligand
G	B	no Ab	dilu9	dilu8	dilu7	dilu6	dilu5	dilu4	dilu3	dilu2	dilu1	B	Test Ab
H	B	B	B	B	B	B	B	B	B	B	B	B	Assay Buffer (B)

Figure 10. Example plate layout showing nonclustered sample locations of test antibody and reference ligand dilution series and wells containing assay buffer (denoted by “B”) alone.

5.C. Preparing Ligand or Antibody Serial Dilutions

The instructions described here are for preparation of a single stock of threefold serial dilutions of a crosslinked ligand for analysis in triplicate (120 μ l of each crosslinked ligand dilution provides a sufficient volume for analysis in triplicate). Alternatively, you can prepare three independent stocks of serial dilutions to generate triplicate samples. To prepare threefold serial dilutions for crosslinked ligand, you will need 400 μ l of reference crosslinked ligand at 3X the highest concentration in your dose response curve. To prepare threefold serial dilutions for test antibodies, you will need 180 μ l of each test antibody at 3X the highest antibody concentration in each of the test antibody dose-response curves. For other dilution schemes, adjust the volumes accordingly.

Note: If you are using 4-1BBL as a control in the assay, use the following instructions to prepare threefold serial dilutions. A threefold serial dilution for test antibodies is shown as an example on the next page.

5.C. Preparing Ligand or Antibody Serial Dilutions (continued)

1. On the day of assay, prepare an appropriate amount of assay buffer as described in Section 5.A.
2. To a sterile, clear V-bottom 96-well plate, add 180µl of reference crosslinked ligand starting dilution (dilu1, 3X final concentration) to wells A11 and B11 (see Figure 11).
3. Add 180µl of test antibodies 1 and 2 starting dilution (dilu1, 3X final concentration) to wells E11 and G11, respectively (Figure 11).
4. Add 120µl of assay buffer to other wells in these four rows, from column 10 to column 2.
5. Transfer 60µl of the crosslinked ligand or antibody starting dilutions from column 11 into column 10. Mix well by pipetting. Avoid creating bubbles.
6. Repeat equivalent threefold serial dilutions across the columns from right to left through column 3. Do not dilute into column 2.
7. Cover the assay plate with a lid and keep at ambient temperature (22–25°C) while preparing the 4-1BB Effector Cells.

Note: Wells A2, B2, E2 and G2 contain 120µl of assay buffer without antibody as a negative control.

Recommended Plate Layout for Antibody Dilutions Prepared from a Single Antibody Stock													
	1	2	3	4	5	6	7	8	9	10	11	12	
A		no Ab	dilu9	dilu8	dilu7	dilu6	dilu5	dilu4	dilu3	dilu2	dilu1		Reference Ligand
B		no Ab	dilu9	dilu8	dilu7	dilu6	dilu5	dilu4	dilu3	dilu2	dilu1		Reference Ligand
C													
D													
E		no Ab	dilu9	dilu8	dilu7	dilu6	dilu5	dilu4	dilu3	dilu2	dilu1		Test Ab 1
F													
G		no Ab	dilu9	dilu8	dilu7	dilu6	dilu5	dilu4	dilu3	dilu2	dilu1		Test Ab 2
H													

Figure 11. Example plate layout showing antibody serial dilutions.

5.D. Preparing 4-1BB Effector Cells

While maintaining the 4-1BB Effector Cells, it is important to follow the recommended cell seeding density. Changes in cell culture volume or seeding density will affect cell growth rate and assay performance. Only use the cells in the assay after the cell doubling rate has stabilized during propagation.

Note: Passaging cells less than 40 hours before the assay is not recommended.

1. Passage the cells two days or three days before performing the assay as described in Section 3.B. To ensure optimal and consistent assay performance, maintain the cell density, upon harvest, in the range of $1.5\text{--}2.0 \times 10^6$ cells/ml and cell viability at greater than 90%.
2. Count the 4-1BB Effector Cells by Trypan blue staining, and calculate the cell density and viability.
3. Transfer an appropriate amount of 4-1BB Effector Cells from the culture vessel to a 50ml conical tube or larger sized centrifuge tube.
4. Collect the cells at $130 \times g$ for 10 minutes at ambient temperature, and resuspend the pellet in assay buffer to generate the targeted cell density of 1.0×10^6 cells/ml.
5. You will need at least 8ml of 4-1BB Effector Cells to fill 120 assay wells, using the inner 60 wells of two assay plates.

5.E. Adding Ligand or Antibody Samples and 4-1BB Effector Cells to Assay Plates

1. Using an electronic multichannel pipette, add 25 μ l of the appropriate antibody or ligand titration to the assay plates according to the plate layout in Figure 10.
2. Add 75 μ l of assay buffer to the outside wells of the 96-well assay plates.
3. Transfer the 4-1BB Effector Cells prepared in Section 5.D to a sterile reagent reservoir. Using a multichannel pipette, dispense 50 μ l (0.5×10^5 cells) of 4-1BB Effector Cells into the wells containing antibody or ligand.
4. Cover each assay plate with a lid and incubate in a 37°C, 5% CO₂ incubator for 6 hours.

5.F. Adding Bio-Glo™ Reagent

Note: Bio-Glo™ Reagent should be at ambient temperature (22–25°C) when added to assay plates.

1. Remove the assay plates from the incubator and equilibrate to ambient temperature for 10–15 minutes.
2. Using a manual multichannel pipette, add 75µl of Bio-Glo™ Reagent to the inner 60 wells of the assay plates, taking care not to create bubbles.
3. Add 75µl of Bio-Glo™ Reagent to wells B1, C1 and D1 of each assay plate to measure the background signal.
4. Incubate at ambient temperature for 5–15 minutes.

Note: Varying the incubation time will affect the raw relative light unit (RLU) values but should not significantly change the EC₅₀ value and fold induction.

5. Measure luminescence using a luminometer or luminescence plate reader.

5.G. Data Analysis

1. Determine the plate background by calculating the average RLU from wells B1, C1 and D1.
2. Calculate fold induction =
$$\frac{\text{RLU (induced-background)}}{\text{RLU (no antibody control-background)}}$$
3. Graph data as RLU versus Log₁₀ [antibody] and fold induction versus Log₁₀ [antibody]. Fit curves and determine the EC₅₀ value of antibody response using appropriate curve fitting software (such as GraphPad Prism® software).

6. Troubleshooting

For questions not addressed here, please contact your local Promega Branch Office or Distributor. Contact information available at: www.promega.com. Email: techserv@promega.com

Symptoms

Causes and Comments

Low luminescence measurements (RLU readout)

Choose an instrument designed for plate-reading luminescence detection. Instruments designed primarily for fluorescence detection are not recommended. Luminometers measure and report luminescence as relative values, and actual RLU numbers will vary between instruments.

Insufficient cells per well can lead to low RLU. Handle and plate cells according to the instructions to ensure a sufficient number of viable cells per well.

Low activity of Bio-Glo™ Reagent leads to low RLU. Store and handle the Bio-Glo™ Reagent according to the instructions.

If performing the assay for the first time, we recommend that you try using the FcγRIIb cells since your Ab of your interest may be dependent on crosslinking by FcγRIIb. In the case of ligands, crosslinking by an antibody may be necessary.

Variability in assay performance

Variations in cell growth conditions including cell plating and harvest density, cell viability and cell doubling time. Ensure consistent cell growth by handling the cells exactly according to the instructions.

Inappropriate cell handling during cell harvest, including long centrifuge times and high centrifuge speeds may cause low assay performance and high assay variation.

Inappropriate cell handling during cell freezing, including long DMSO exposure times before freezing may cause low assay performance and high assay variation.

Inappropriate cell counting methods may lead to variation in cell numbers in culture and assays and cause high assay variation. Ensure accurate and consistent cell counting methods.

6. Troubleshooting (continued)

Symptoms

Weak assay response (low fold induction)

Causes and Comments

Optimize the concentration range of your test sample(s) to achieve a full dose response with complete upper and lower asymptotes. The EC₅₀ value obtained in the 4-1BB Bioassay may vary from the EC₅₀ value obtained using other methods such as primary T cell-based assays.

Determine if the antibody used is dependent on crosslinking for performance by testing in the presence of FcγRIIb cells.

If untreated control RLU is less than 100-fold above plate reader background RLU, subtract plate background RLU from all samples before calculating fold induction.

7. References

1. Mahoney, K.M., Rennert, P.D. and Freeman, G.J. (2015) Combination cancer immunotherapy and new immunomodulatory targets. *Nat. Rev. Drug Discov.* **14**, 561–84.
2. Melero, I. *et al.* (2015) Evolving synergistic combinations of targeted immunotherapies to combat cancer. *Nat. Rev. Cancer* **15**, 457–72.
3. Chester, C. *et al.* (2018) Immunotherapy targeting 4-1BB: Mechanistic rationale, clinical results, and future strategies. *Blood* **131**, 49–57.
4. Chester, C., Ambulkar, S. and Kohrt, H.E. (2016) 4-1BB agonism: Adding the accelerator to cancer immunotherapy. *Cancer Immunol. Immunother.* **65**, 1234–8.
5. Lee, H.W. *et al.* (2014) 4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1. *J. Immunol.* **169**, 4882–8.
6. Snell, L.M. *et al.* (2011) T-cell intrinsic effects of GITR and 4-1BB during viral infection and cancer immunotherapy. *Immunol Rev.* **244**, 197–217.
7. White, A.L. *et al.* (2011) Interaction with FcγRIIb is critical for the agonistic activity of anti-CD40 monoclonal antibody. *J. Immunol.* **187**, 1754–63.
8. Wilson, N.S. *et al.* (2011) An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. *Cancer Cell* **19**, 101–13.
9. Wang, J. *et al.* (2018) Cell-based reporter bioassays to evaluate the FcγR-dependent agonist activity of therapeutic antibodies against co-stimulatory receptors. *American Association of Cancer Research (AACR) Annual meeting*, Poster abstract #2732.

8. Appendix

8.A. Representative Assay Results with FcγRIIb-Dependent Antibody




Figure 12. The 4-1BB Bioassay measures the activity of Control Ab, Anti-4-1BB. FcγRIIb CHO-K1 Cells were plated overnight. The following day, a titration of Control Ab, Anti-4-1BB, (Section 4.C) was added followed by 4-1BB Effector Cells. After 6 hours of induction at 37°C, Bio-Glo™ Reagent was added, and luminescence was determined using a GloMax® Discover System. Four-parameter logistic curve analysis was performed with GraphPad Prism® software. The EC₅₀ response determined was 0.14µg/ml, and the fold induction was 49.1

8.B. Representative Assay Results with Crosslinked 4-1BB Ligand




Figure 13. The 4-1BB Bioassay measures the activity of crosslinked 4-1BB Ligand. On the assay day, 4-1BB Effector Cells were plated in a 96-well plate at 50,000 cells/well. Cells were incubated with various concentrations of crosslinked 4-1BBL (Section 5.C). After 6 hours induction at 37°C, Bio-Glo™ Reagent was added, and luminescence was determined using a GloMax® Discover System. Four-parameter logistic curve analysis was performed with GraphPad Prism® software. The EC₅₀ response determined was ~0.076µg/ml, and the fold induction was 12.9.

8.C. Composition of Buffers and Solutions

initial cell culture medium for 4-1BB Effector Cells

90% RPMI 1640 with L-glutamine and HEPES
10% FBS
1mm sodium pyruvate
0.1mm MEM nonessential amino acids

cell growth medium for 4-1BB Effector Cells

90% RPMI 1640 with L-glutamine and HEPES
10% FBS
500µg/ml hygromycin B
800µg/ml G418 sulfate solution
1mm sodium pyruvate
0.1mm MEM nonessential amino acids

cell freezing medium for 4-1BB Effector Cells

85% RPMI 1640 with L-glutamine and HEPES
10% FBS
5% DMSO

cell recovery medium for FcγRIIb CHO-K1 Cells

90% Ham's F12
10% FBS

assay buffer

99% RPMI 1640 with L-glutamine and HEPES
1% FBS

9. Summary of Changes

The following changes were made to the 5/26 revision of this document:

1. Removed Section 8.D, Related Products.
2. Made minor text and formatting edits.



^(a)NOT FOR MEDICAL DIAGNOSTIC USE. FOR IN VITRO USE ONLY. BY USE OF THIS PRODUCT, RECIPIENT AGREES TO BE BOUND BY THE TERMS OF THIS LIMITED USE STATEMENT. If the recipient is not willing to accept the conditions of this limited use statement, and the product is unused, Promega will accept return of the unused product and provide the recipient with a full refund.

This product may not be further sold or transferred by the recipient and may be used only by the recipient, and then only for (1) research use, (2) discovery, development and monitoring of biologic drugs and vaccines, (3) quality assurance testing of biologic drugs and vaccines, and (4) product release assays for biologic drugs and vaccines. No other commercial use is allowed. "Commercial use" means any and all uses of this product by recipient for monetary or other consideration, including providing a service, information or data to unaffiliated third parties, and resale of this product for any use. Recipient has no right to modify, derivatize, genetically engineer or otherwise create variations of the cells or genes stably transfected within the cells except that recipient may propagate and store the cells for long-term use. In addition, recipient must use Bio-Glo™ Luciferase Assay System purchased from Promega Corporation for all luminescence assays using this product or contact Promega to obtain a license for use of this product with reagents other than Promega's. PROMEGA MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING AS TO MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH REGARDS TO THIS PRODUCT. The terms of this agreement shall be governed under the laws of the State of Wisconsin, USA.

^(b)U.S. Pat. No. 8,008,006.

^(c)Licensed from Lonza Cologne GmbH under U.S. Pat. Nos. 7,700,357, 8,192,990 and 8,003,389, European Pat. Nos. 1297119, 1522587, 1607484 and 1741778 and other pending and issued patents

^(d)Patent Pending.

© 2019–2026 Promega Corporation. All Rights Reserved.

GloMax and Lumit are registered trademarks of Promega Corporation. Bio-Glo and Bio-Glo-NL are trademarks of Promega Corporation.

Accutase is a registered trademark of Innovative Cell Technologies. Corning and Costar are registered trademarks of Corning, Inc. Echo is a registered trademark of Labcyte, Inc. GIBCO is a registered trademark of Life Technologies Corporation. GraphPad Prism is a registered trademark of GraphPad Software, Inc. JMP is a registered trademark of SAS Institute, Inc. Mantis is a registered trademark of Formulatrix, Inc. Multidrop is a trademark of Thermo Fisher Scientific, Ltd.

Products may be covered by pending or issued patents or may have certain limitations. Please visit our website for more information.

All prices and specifications are subject to change without prior notice.

Product claims are subject to change. Please contact Promega Technical Services or access the Promega online catalog for the most up-to-date information on Promega products.